Published in J Urol on December 01, 2002
Targeted hyperthermia using metal nanoparticles. Adv Drug Deliv Rev (2009) 2.12
Radio frequency ablation of small renal tumors:: intermediate results. J Urol (2004) 1.13
Radiofrequency ablation of renal tumors. Eur Radiol (2004) 0.88
Radiofrequency-assisted laparoscopic partial nephrectomy: clinical and histologic results. J Endourol (2007) 0.79
Cryoablation for small renal masses. Adv Urol (2008) 0.79
Editorial: Kidney cancer--a unique opportunity for the development of disease specific therapy. J Urol (2002) 0.78
Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. Can Urol Assoc J (2009) 0.78
Laparoscopic radiofrequency ablation-assisted enucleation of Xp11.2 translocation renal cell carcinoma: A case report. Oncol Lett (2014) 0.77
Percutaneous US-guided RF thermal ablation for malignant renal tumors: preliminary results in 13 patients. Eur Radiol (2004) 0.76
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Classic signs in uroradiology. Radiographics (2004) 3.53
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Iron and cancer: more ore to be mined. Nat Rev Cancer (2013) 2.40
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A (2010) 1.99
A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology (2004) 1.99
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
MR urography: techniques and clinical applications. Radiographics (2008) 1.85
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging (2013) 1.82
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Complications of ureteral stent placement. Radiographics (2002) 1.79
Iron chelators in cancer chemotherapy. Curr Top Med Chem (2004) 1.61
Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR Am J Roentgenol (2004) 1.56
TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med (2005) 1.52
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
Ferritin for the clinician. Blood Rev (2008) 1.46
Demand for continuing medical education programs on cancer care among primary care physicians in North Carolina. N C Med J (2004) 1.46
Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol (2003) 1.45
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res (2004) 1.41
Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A (2009) 1.34
Percutaneous nephrostomy with extensions of the technique: step by step. Radiographics (2002) 1.33
Ironing out cancer. Cancer Res (2011) 1.25
Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res (2004) 1.24
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem (2002) 1.23
Staging and current treatment of hepatocellular carcinoma. Radiographics (2005) 1.23
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Iron chelation in the biological activity of curcumin. Free Radic Biol Med (2006) 1.17
The role of iron chelation in cancer therapy. Curr Med Chem (2003) 1.15
Excess capacity of the iron regulatory protein system. J Biol Chem (2007) 1.14
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Imaging-guided percutaneous ablation of renal cell carcinoma: a primer of how we do it. AJR Am J Roentgenol (2009) 1.13
Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res (2003) 1.13
Computerized tomography guided access for percutaneous nephrostolithotomy. J Urol (2003) 1.12
Neuroblastoma in an adult. Urology (2004) 1.12
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol (2009) 1.10
Bioinformatics tools for cancer metabolomics. Metabolomics (2011) 1.10
Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis (2009) 1.09
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood (2005) 1.08
Prostate abscess following intravesical bacillus Calmette-Guerin treatment. J Urol (2002) 1.06
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging (2010) 1.05
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr (2002) 1.03
Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis (2008) 1.03
A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst (2009) 1.02
A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell (2007) 1.01
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res (2005) 1.01
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol (2008) 1.01
CT and MR imaging after imaging-guided thermal ablation of renal neoplasms. Radiographics (2007) 0.99
DNA damage levels in prostate cancer cases and controls. Carcinogenesis (2005) 0.98
The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials (2012) 0.97
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology (2006) 0.97
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
IRP2 regulates breast tumor growth. Cancer Res (2013) 0.94
Microwave ablation of renal parenchymal tumors before nephrectomy: phase I study. AJR Am J Roentgenol (2007) 0.94
Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem (2002) 0.94
Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. AJR Am J Roentgenol (2005) 0.93
Bladder cancer. Curr Opin Oncol (2003) 0.93
Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. Nanomedicine (Lond) (2011) 0.92
Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials (2011) 0.92
Serum levels of phytanic acid are associated with prostate cancer risk. Prostate (2005) 0.92
The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model. J Urol (2011) 0.91
Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology (2003) 0.90
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Randomized prospective trial of a novel local anesthetic technique for extensive prostate biopsy. Urology (2003) 0.89
Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J (2002) 0.89
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate (2012) 0.89
Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One (2011) 0.89
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat (2010) 0.89
Utility of frozen section analysis of resection margins during partial nephrectomy. Urology (2004) 0.89
Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo. Biochem J (2006) 0.89
Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. Am J Manag Care (2008) 0.88
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol (2004) 0.88
A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy (2014) 0.88
Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Oncol (2007) 0.87
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2007) 0.87
Bladder cancer. Curr Opin Oncol (2005) 0.87
Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate (2012) 0.86
IgD-kappa myeloma: an unusual case. Ann Clin Lab Sci (2003) 0.86
Bladder cancer. Curr Opin Oncol (2002) 0.85
Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res (2003) 0.85
Bladder cancer. Curr Opin Oncol (2004) 0.84
Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One (2012) 0.84
Ferritin regulation by oxidants and chemopreventive xenobiotics. Adv Enzyme Regul (2003) 0.83
Complementary and alternative medicine for advanced prostate cancer. Urol Clin North Am (2006) 0.82
Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors. J Exp Clin Cancer Res (2010) 0.82
Ferritin H induction by histone deacetylase inhibitors. Biochem Pharmacol (2010) 0.82
Computed tomography-guided renal tumor biopsies: tumor imaging features affecting sample adequacy. J Comput Assist Tomogr (2013) 0.81